Holver Parada
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Holver Parada has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
- Fabian Galvis
Grupo de Investigación Majumba, Facultad de Ciencias Básicas, Universidad Francisco de Paula Santander, Cúcuta 540003, Norte de Santander, Colombia
1 shared publication - Javier Andrés Soto
Facultad de Ciencias Médicas y de la Salud, Instituto de Investigación Masira, University of Santander, Bucaramanga, Santander, 540003
1 shared publication - Julio César Villegas-Pineda
Departamento de Microbiología y Patología, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara 44340, Mexico
1 shared publication - Mélida del Rosario Lizarazo-Taborda
Laboratorio de Investigación en Cáncer e Infecciones (LICI), Departamento de Microbiología y Patología, CUCS, UDG, Guadalajara 44340, Jalisco, Mexico
1 shared publication
Latest Publications
- Open Access
- 1 April 2026
- Published by MDPI AG in Epigenomes
- Vol. 10 (2) , 23
Natural Compounds as Epimodulators in Epithelial Ovarian Cancer
Epithelial ovarian carcinoma (EOC) is the most common type of ovarian cancer and represents the most lethal gynecologic neoplasm. EOC is usually diagnosed at late stages due to its nonspecific signs and symptoms. Although significant clinical advances have been made in other types of malignancies, EOC remains a disease that requires further biological research to identify new therapeutic targets or new treatment alternatives, as conventional approaches are often ineffective or lead to the development of resistance and unwanted side effects. There are a significant number of natural products from which commercially available drugs have been derived, largely for the treatment of cancer, but none of them focus on epigenetic changes in specific targets in EOC. Based on the above, this work focuses on describing the in vitro and in vivo findings from the last twelve years derived from the action of important phytochemicals on epigenetic targets in ovarian cancer, among other mechanisms of action, revealing that there is a significant gap to be bridged in terms of the transition from basic to applied research regarding the potential of plant-derived molecules as possible epidrugs in EOC.
- 1 April 2026
- Published by MDPI AG in Epigenomes
- Vol. 10 (2) , 23
Open AccessNatural Compounds as Epimodulators in Epithelial Ovarian Cancer
Epithelial ovarian carcinoma (EOC) is the most common type of ovarian cancer and represents the most lethal gynecologic neoplasm. EOC is usually diagnosed at late stages due to its nonspecific signs and symptoms. Although significant clinical advances have been made in other types of malignancies, EOC remains a disease that requires further biological research to identify new therapeutic targets or new treatment alternatives, as conventional approaches are often ineffective or lead to the development of resistance and unwanted side effects. There are a significant number of natural products from which commercially available drugs have been derived, largely for the treatment of cancer, but none of them focus on epigenetic changes in specific targets in EOC. Based on the above, this work focuses on describing the in vitro and in vivo findings from the last twelve years derived from the action of important phytochemicals on epigenetic targets in ovarian cancer, among other mechanisms of action, revealing that there is a significant gap to be bridged in terms of the transition from basic to applied research regarding the potential of plant-derived molecules as possible epidrugs in EOC.